scispace - formally typeset
E

Eric Levy

Publications -  20
Citations -  646

Eric Levy is an academic researcher. The author has contributed to research in topics: Docetaxel & Cancer. The author has an hindex of 9, co-authored 20 publications receiving 581 citations.

Papers
More filters
Journal ArticleDOI

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.

TL;DR: The combination of TG4010 with standard chemotherapy in advanced non-small cell lung cancer is feasible and shows encouraging results, with mild to moderate injection site reactions, flu-like symptoms, and fatigue being the most frequent adverse reactions.
Journal ArticleDOI

Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand

TL;DR: FG significantly reduces the nail and skin toxicity associated with docetaxel and provides a new tool in supportive care management to improve a patient's quality of life.
Journal ArticleDOI

A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines.

TL;DR: A Fluorospot assay to detect single cells that simultaneously produce multiple cytokines that will be useful for detailed analysis of T lymphocytes in various disease states in which an imbalance of T cell subpopulations is suspected, but will also provide a better characterization of polarized specific immune responses.
Journal ArticleDOI

Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot

TL;DR: The efficacy and safety of an Elasto‐Gel frozen sock was investigated for the prevention of docetaxel‐induced nail and skin toxicity of the feet.
Journal ArticleDOI

What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

TL;DR: To determine the benefit of starting early chemotherapy with docetaxel (the recommended first‐line treatment) for patients with asymptomatic metastatic metastatic hormone‐refractory prostate cancer (HRPC).